Evidence map›Paper›PMID 18926645›Full record

Trial reportDrug and alcohol dependence2009

Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy.

Craig R Rush, William W Stoops, Lon R Hays

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Dopamine agonists for the treatment of cocaine dependence.The Cochrane database of systematic reviews · 2015
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Human laboratory models of reward in substance use disorder.Pharmacology, biochemistry, and behavior · 2024
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Agonist Medications for the Treatment of Cocaine Use Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Craig R RushDepartment of Behavioral Science, University of Kentucky College of Medicine, College of Medicine Office Building, Lexington, KY 40536-0086, USA. crush2@email.uky.edu
William W Stoops
Lon R Hays
University of Kentucky · US

Funding

XENOBIOTIC TRANSFER INTO MILK NITROFURANTOINM01RR002602 · NCRR · UNIVERSITY OF KENTUCKY · PI JICHA, GREGORY A · 1985 to 2007
$12.1M
Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel MedicationsR01DA021155 · NIDA · UNIVERSITY OF KENTUCKY · PI RUSH, CRAIG R · 2006 to 2009
$1.4M
NCRR NIH HHS M01 RR02602NIDA NIH HHS R01 DA 021155NIDA NIH HHS R01 DA021155
6 · The paper itself

Abstract

Agonist replacement therapies are effective for managing substance abuse disorders including nicotine and opioid dependence. The results of preclinical laboratory studies and clinical trials indicate that agonist replacements like D-amphetamine may be a viable option for managing cocaine dependence. This experiment determined the physiological and behavioral effects of cocaine during D-amphetamine maintenance in seven cocaine-dependent participants. We predicted cocaine would be well tolerated during D-amphetamine maintenance. We also predicted D-amphetamine would attenuate the behavioral effects of cocaine. After 3-5 days of D-amphetamine maintenance (0, 15, and 30 mg/day), volunteers were administered ascending doses of cocaine (4, 30, 60 mg, i.n.) within a single session. Cocaine doses were separated by 90 min. Cocaine produced prototypical physiological (e.g., increased heart rate, blood pressure, and body temperature) and subject-rated (e.g., increased ratings of Good Effects) effects. During maintenance on the highest D-amphetamine dose, the heart rate increasing effects of cocaine were larger than observed during placebo maintenance. These effects were not clinically significant and no unexpected or serious adverse events were observed. D-amphetamine attenuated some of the subject-rated effects of cocaine. These results are concordant with those of previous preclinical studies, human laboratory experiments and clinical trials, further suggesting that agonist replacement therapy may be a viable strategy for managing cocaine abuse. Additional research in humans is needed to determine whether D-amphetamine attenuates the effects of cocaine under different experimental conditions (e.g., higher cocaine doses) and behavioral arrangements (e.g., drug self-administration or discrimination).

Indexed as

Administration, IntranasalAdultBlood PressureBody TemperatureCentral Nervous System StimulantsCocaineCocaine-Related DisordersDelayed-Action PreparationsDextroamphetamineDose-Response Relationship, DrugDouble-Blind MethodFemaleHeart RateHumansMaleMiddle AgedCentral Nervous System StimulantsCocaineDelayed-Action PreparationsDextroamphetamine

Identifiers

PMID18926645
PMCPMC2663379
OpenAlexW1988129076

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.